SK10392003A3 - Farmaceutické prostriedky na liečenie demyelinizačných ochorení alebo stavov - Google Patents

Farmaceutické prostriedky na liečenie demyelinizačných ochorení alebo stavov Download PDF

Info

Publication number: SK10392003A3
Authority: SK; Slovakia
Prior art keywords: carbon atoms; group; alkyl; compound; hydrogen atom
Prior art date: 2001-02-15

Application number

SK1039-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Craig P. Smith

Michel P. Rathbone

Margaret Petty

David Rampe

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-15

Filing date

2002-02-14

Publication date

2004-01-08

2002-02-14 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2004-01-08 Publication of SK10392003A3 publication Critical patent/SK10392003A3/sk

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Hematology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

SK1039-2003A 2001-02-15 2002-02-14 Farmaceutické prostriedky na liečenie demyelinizačných ochorení alebo stavov SK10392003A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US26884601P	2001-02-15	2001-02-15
GBGB0119435.6A GB0119435D0 (en)	2001-02-15	2001-08-09	Method of treating of demyelinating diseases or conditions
PCT/US2002/005501 WO2002064126A2 (en)	2001-02-15	2002-02-14	Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number	Publication Date
SK10392003A3 true SK10392003A3 (sk)	2004-01-08

Family

ID=23024747

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1039-2003A SK10392003A3 (sk)	2001-02-15	2002-02-14	Farmaceutické prostriedky na liečenie demyelinizačných ochorení alebo stavov

Country Status (39)

Country	Link
US (10)	US6967210B2 (hr)
EP (1)	EP1368031A2 (hr)
JP (3)	JP2004518711A (hr)
KR (3)	KR100951542B1 (hr)
CN (2)	CN1529598A (hr)
AP (1)	AP1749A (hr)
AR (1)	AR035750A1 (hr)
AU (3)	AU2002247200B9 (hr)
BR (1)	BR0207272A (hr)
CA (1)	CA2438712A1 (hr)
CO (1)	CO5390085A1 (hr)
CR (1)	CR7023A (hr)
CZ (1)	CZ20032172A3 (hr)
EA (2)	EA012409B1 (hr)
EC (1)	ECSP024218A (hr)
EE (1)	EE200300363A (hr)
GB (1)	GB0119435D0 (hr)
HK (1)	HK1080361B (hr)
HR (1)	HRP20030652A2 (hr)
HU (1)	HUP0303203A3 (hr)
IL (2)	IL157341A0 (hr)
MA (1)	MA26152A1 (hr)
ME (1)	MEP21208A (hr)
MX (1)	MXPA03006110A (hr)
MY (1)	MY157745A (hr)
NO (1)	NO20033622L (hr)
NZ (4)	NZ544720A (hr)
OA (1)	OA12549A (hr)
PA (1)	PA8540101A1 (hr)
PE (1)	PE20040175A1 (hr)
PL (1)	PL363638A1 (hr)
SG (1)	SG134170A1 (hr)
SK (1)	SK10392003A3 (hr)
TR (4)	TR200800693T2 (hr)
TW (1)	TWI325319B (hr)
UA (2)	UA80394C2 (hr)
WO (1)	WO2002064126A2 (hr)
YU (1)	YU62903A (hr)
ZA (1)	ZA200306124B (hr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions
JP2006511624A (ja) *	2002-12-20	2006-04-06	ダイノジェンファーマシューティカルズ，インコーポレイテッド	α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
WO2004066990A2 (en) *	2003-01-30	2004-08-12	Dynogen Pharmaceuticals, Inc.	Methods of treating lower urinary tract disorders using sodium channel modulators
ES2275229T3 (es) *	2003-03-21	2007-06-01	Dynogen Pharmaceuticals, Inc.	Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
GT200500063A (es) *	2004-04-01	2005-10-14		Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) *	2005-04-28	2005-06-22	Paradigm Therapeutics Ltd	Ion channel
FR2892021B1 (fr) *	2005-10-19	2008-01-04	Urogene	Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) *	2005-10-19	2008-01-04	Urogene Sa	Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) *	2006-06-16	2013-04-16	Landon C. G. Miller	Compositions and methods for regulating membrane potential
DE102008044844B4 (de) *	2008-08-28	2018-08-30	Siemens Healthcare Gmbh	Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) *	2010-03-26	2015-08-26	株式会社半导体能源研究所	半导体器件
US20130184316A1 (en) *	2010-07-15	2013-07-18	Andrew Hornstein	Methods for diagnosing and treating concussive disorders
BR112013019265A2 (pt) *	2011-01-28	2016-10-11	Acorda Therapeutics Inc	uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
TWI592156B (zh) *	2011-10-04	2017-07-21	艾可達醫療公司	使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (en)	2016-02-29	2017-09-08	University Of Florida Research Foundation, Incorporated	Chemotherapeutic methods
EP3727587A4 (en) *	2017-12-22	2022-02-23	Massachusetts Institute Of Technology	COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
CA3207205A1 (en) *	2021-01-20	2022-07-28	Rush University Medical Center	Improved treatment for globoid cell leukodsytrophy or krabbe disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4970218A (en) *	1987-04-24	1990-11-13	Hoechst-Roussel Pharmaceuticals Inc.	N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (en) *	1987-04-24	1994-12-07	Hoechst-Roussel Pharmaceuticals Incorporated	N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments
US4880822A (en) *	1987-04-24	1989-11-14	Hoechst-Roussel Pharmaceuticals, Inc.	N-(pyridinyl)-1H-indol-1-amines
IL95251A (en) *	1989-08-02	1996-08-04	Hoechst Roussel Pharma	2,3-Dihydro-1- (pyridinylamino) - indoles, a method for their preparation and use as drugs
US5214038A (en) *	1991-04-15	1993-05-25	Hoechst-Roussel Pharmaceuticals Inc.	1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) *	1993-07-29	1995-02-02	Boehringer Ingelheim Kg	Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5459274A (en) *	1994-05-13	1995-10-17	Hoechst-Roussel Pharmaceuticals Inc.	Preparation of N-alkyl-N-pyridinyl-1H-indol-1-amines
US5565475A (en) *	1994-11-08	1996-10-15	Muhlhauser; Mark A.	Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (en) *	1995-03-10	1996-09-11	Boehringer Mannheim Gmbh	Method of manufacturing a therapeutic agent for the regeneration of oligodendrocytes
FR2754147B1 (fr)	1996-10-03	2000-02-04	Mbh Technologies Sa	Installation et procede pour le traitement de carcasses
ATE252590T1 (de) *	1998-01-29	2003-11-15	Bristol Myers Squibb Co	Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
AU5483500A (en) *	1999-07-09	2001-01-30	Ortho-Mcneil Pharmaceutical, Inc.	Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) *	2001-02-15	2001-10-03	Aventis Pharm Prod Inc	Method of treating of demyelinating diseases or conditions

2001
- 2001-08-09 GB GBGB0119435.6A patent/GB0119435D0/en not_active Ceased
2002
- 2002-02-14 TR TR2008/00693T patent/TR200800693T2/xx unknown
- 2002-02-14 CZ CZ20032172A patent/CZ20032172A3/cs unknown
- 2002-02-14 UA UA2003098376A patent/UA80394C2/uk unknown
- 2002-02-14 YU YU62903A patent/YU62903A/sh unknown
- 2002-02-14 AU AU2002247200A patent/AU2002247200B9/en not_active Ceased
- 2002-02-14 JP JP2002563920A patent/JP2004518711A/ja not_active Ceased
- 2002-02-14 EE EEP200300363A patent/EE200300363A/xx unknown
- 2002-02-14 US US10/076,191 patent/US6967210B2/en not_active Expired - Lifetime
- 2002-02-14 SG SG200505802-9A patent/SG134170A1/en unknown
- 2002-02-14 TR TR2008/00692T patent/TR200800692T2/xx unknown
- 2002-02-14 OA OA1200300199A patent/OA12549A/en unknown
- 2002-02-14 EA EA200600896A patent/EA012409B1/ru not_active IP Right Cessation
- 2002-02-14 EP EP02714974A patent/EP1368031A2/en not_active Withdrawn
- 2002-02-14 NZ NZ544720A patent/NZ544720A/en unknown
- 2002-02-14 CN CNA028048644A patent/CN1529598A/zh active Pending
- 2002-02-14 KR KR1020087031855A patent/KR100951542B1/ko not_active IP Right Cessation
- 2002-02-14 ME MEP-212/08A patent/MEP21208A/hr unknown
- 2002-02-14 NZ NZ556697A patent/NZ556697A/en unknown
- 2002-02-14 WO PCT/US2002/005501 patent/WO2002064126A2/en active Application Filing
- 2002-02-14 NZ NZ539159A patent/NZ539159A/en unknown
- 2002-02-14 CN CNB2005100597348A patent/CN100522164C/zh not_active Expired - Fee Related
- 2002-02-14 TR TR2008/00691T patent/TR200800691T2/xx unknown
- 2002-02-14 BR BR0207272-6A patent/BR0207272A/pt not_active IP Right Cessation
- 2002-02-14 HU HU0303203A patent/HUP0303203A3/hu unknown
- 2002-02-14 SK SK1039-2003A patent/SK10392003A3/sk unknown
- 2002-02-14 KR KR1020037010691A patent/KR100951540B1/ko not_active IP Right Cessation
- 2002-02-14 TR TR2003/01330T patent/TR200301330T2/xx unknown
- 2002-02-14 NZ NZ527011A patent/NZ527011A/en unknown
- 2002-02-14 IL IL15734102A patent/IL157341A0/xx unknown
- 2002-02-14 CA CA002438712A patent/CA2438712A1/en not_active Abandoned
- 2002-02-14 EA EA200300882A patent/EA011319B1/ru not_active IP Right Cessation
- 2002-02-14 KR KR1020087031854A patent/KR20090005254A/ko not_active Application Discontinuation
- 2002-02-14 MX MXPA03006110A patent/MXPA03006110A/es active IP Right Grant
- 2002-02-14 PL PL02363638A patent/PL363638A1/xx not_active Application Discontinuation
- 2002-02-14 AP APAP/P/2003/002834A patent/AP1749A/en active
- 2002-02-15 CO CO02013025A patent/CO5390085A1/es not_active Application Discontinuation
- 2002-02-15 AR ARP020100540A patent/AR035750A1/es unknown
- 2002-02-15 EC EC2002004218A patent/ECSP024218A/es unknown
- 2002-02-15 MY MYPI20020518A patent/MY157745A/en unknown
- 2002-02-15 TW TW091102861A patent/TWI325319B/zh not_active IP Right Cessation
- 2002-02-18 PA PA20028540101A patent/PA8540101A1/es unknown
- 2002-02-26 PE PE2002000159A patent/PE20040175A1/es not_active Application Discontinuation
2003
- 2003-07-11 MA MA27235A patent/MA26152A1/fr unknown
- 2003-07-16 CR CR7023A patent/CR7023A/es unknown
- 2003-08-07 ZA ZA200306124A patent/ZA200306124B/xx unknown
- 2003-08-11 IL IL157341A patent/IL157341A/en not_active IP Right Cessation
- 2003-08-13 HR HR20030652A patent/HRP20030652A2/hr not_active Application Discontinuation
- 2003-08-14 NO NO20033622A patent/NO20033622L/no not_active Application Discontinuation
2004
- 2004-02-03 US US10/770,655 patent/US20040157888A1/en not_active Abandoned
- 2004-02-03 US US10/770,656 patent/US20040157889A1/en not_active Abandoned
2005
- 2005-03-14 US US11/079,366 patent/US7179821B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/079,327 patent/US7230015B2/en not_active Expired - Lifetime
- 2005-09-27 US US11/236,145 patent/US7534803B2/en not_active Expired - Fee Related
2006
- 2006-01-05 HK HK06100186.8A patent/HK1080361B/zh not_active IP Right Cessation
- 2006-04-04 UA UAA200603708A patent/UA88773C2/ru unknown
2008
- 2008-03-13 AU AU2008201179A patent/AU2008201179B2/en not_active Ceased
2009
- 2009-04-06 JP JP2009091807A patent/JP2009185045A/ja not_active Abandoned
- 2009-04-29 US US12/420,407 patent/US20090209594A1/en not_active Abandoned
- 2009-04-29 US US12/420,381 patent/US20090270458A1/en not_active Abandoned
- 2009-04-29 US US12/420,390 patent/US20090281147A1/en not_active Abandoned
- 2009-04-29 US US12/420,416 patent/US20090209595A1/en not_active Abandoned
- 2009-11-19 AU AU2009238332A patent/AU2009238332A1/en not_active Abandoned
2010
- 2010-02-16 JP JP2010030929A patent/JP2010120958A/ja not_active Abandoned

Also Published As

Publication number	Publication date
AU2002247200B2 (en)	2007-12-13
HK1080361A1 (en)	2006-04-28
US7534803B2 (en)	2009-05-19
TR200800691T2 (tr)	2008-03-21
PA8540101A1 (es)	2003-09-05
AU2002247200B9 (en)	2008-07-10
HUP0303203A3 (en)	2007-11-28
EP1368031A2 (en)	2003-12-10
JP2009185045A (ja)	2009-08-20
EA200600896A1 (ru)	2006-08-25
US20090209594A1 (en)	2009-08-20
BR0207272A (pt)	2004-02-10
TR200301330T2 (tr)	2004-12-21
PE20040175A1 (es)	2004-03-29
US20090270458A1 (en)	2009-10-29
YU62903A (sh)	2006-05-25
US20050159456A1 (en)	2005-07-21
AP1749A (en)	2007-06-13
US7230015B2 (en)	2007-06-12
EA200300882A1 (ru)	2003-12-25
OA12549A (en)	2006-06-05
MY157745A (en)	2016-07-15
TR200800692T2 (tr)	2008-03-21
WO2002064126A3 (en)	2003-02-20
US20040157889A1 (en)	2004-08-12
US20040157888A1 (en)	2004-08-12
CO5390085A1 (es)	2004-04-30
KR100951540B1 (ko)	2010-04-09
TWI325319B (en)	2010-06-01
US20090281147A1 (en)	2009-11-12
NO20033622D0 (no)	2003-08-14
AP2003002834A0 (en)	2003-09-30
PL363638A1 (en)	2004-11-29
AU2008201179A1 (en)	2008-04-03
JP2010120958A (ja)	2010-06-03
CN1529598A (zh)	2004-09-15
UA88773C2 (ru)	2009-11-25
IL157341A0 (en)	2004-02-19
MA26152A1 (fr)	2004-07-01
UA80394C2 (en)	2007-09-25
KR20040014459A (ko)	2004-02-14
IL157341A (en)	2010-11-30
NZ539159A (en)	2006-11-30
US7179821B2 (en)	2007-02-20
SG134170A1 (en)	2007-08-29
MEP21208A (hr)	2010-06-10
US6967210B2 (en)	2005-11-22
ZA200306124B (en)	2004-11-08
CN100522164C (zh)	2009-08-05
NZ527011A (en)	2005-07-29
AR035750A1 (es)	2004-07-07
EA011319B1 (ru)	2009-02-27
AU2009238332A1 (en)	2009-12-10
HK1080361B (zh)	2009-10-30
NO20033622L (no)	2003-10-06
ECSP024218A (es)	2003-09-24
KR20090005255A (ko)	2009-01-12
KR100951542B1 (ko)	2010-04-09
CN1679564A (zh)	2005-10-12
JP2004518711A (ja)	2004-06-24
KR20090005254A (ko)	2009-01-12
HUP0303203A2 (hu)	2003-12-29
GB0119435D0 (en)	2001-10-03
CZ20032172A3 (cs)	2004-01-14
AU2008201179B2 (en)	2009-08-20
NZ556697A (en)	2009-01-31
US20050234105A1 (en)	2005-10-20
HRP20030652A2 (en)	2005-06-30
US20030105150A1 (en)	2003-06-05
CR7023A (es)	2003-11-17
EE200300363A (et)	2003-10-15
CA2438712A1 (en)	2002-08-22
US20090209595A1 (en)	2009-08-20
WO2002064126A2 (en)	2002-08-22
MXPA03006110A (es)	2005-07-01
EA012409B1 (ru)	2009-10-30
TR200800693T2 (tr)	2008-07-21
NZ544720A (en)	2007-08-31
US20060025452A1 (en)	2006-02-02

Legal Events

Date	Code	Title	Description
2011-07-06	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
US7534803B2 (en)	2009-05-19	Method of treating demyelinating diseases or conditions
Askmark et al.	1993	A pilot trial of dextromethorphan in amyotrophic lateral sclerosis.
AU2002247200A1 (en)	2003-02-20	Method of treating of demyelinating diseases or conditions
CH650926A5 (de)	1985-08-30	Antiparkinson-mittel.
KR100301415B1 (ko)	2001-11-22	신경병치료에있어서4-아미노피리딘의사용
EP0608671B1 (en)	1996-09-18	Use of 3-indolepyruvic acid to reduce the level of glucocorticoids in the blood and to prevent cerebral disturbances
US20230165852A1 (en)	2023-06-01	Method for treating central nervous system disorders using dopamine d3 partial agonists
Hara et al.	1995	Evaluation of acute haemodynamic response to high-dose naloxone in young hypertensive and normotensive humans